Background And Aims: Coronary in-stent restenosis (ISR) is an important complication of percutaneous coronary intervention (PCI). However, the relationship between lipoprotein associated phospholipase A2 (Lp-PLA2) level and ISR after PCI is rarely reported. This study aims to explore the relationship between Lp-PLA2 and the occurrence of ISR at post-PCI and its predictive value for ISR.
Methods And Results: Plasma Lp-PLA2 mass were measured in 847 patients planting 1262 stents and evaluated along with known risk indicators. One-year angiographic follow-up showed that baseline elevated Lp-PLA2 mass was strongly associated with early restenosis (95% CI = 1.062-3.050, P < 0.05). Beyond the first year, the occurrence of late restenosis (95% CI = 1.043-3.214, P < 0.05) was significantly larger in the elevated Lp-PLA2 group. Kaplan-Meier analysis after three-year clinical follow up suggested that Lp-PLA2 mass did add the positive effect on the occurrence of major adverse cardiovascular events (MACEs).
Conclusion: In conclusion, increased baseline plasma Lp-PLA2 predicts increased risks of re-stenosis and MACEs, which may be a novel biomarker for predicting ISR and MACEs.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/00369330211034809 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Association of PLA2G7 Gene Polymorphisms with Serum Lp-PLA2 Activity and Lipid Profile in Han Chinese Patients with Coronary Heart Disease.
Pharmgenomics Pers Med
December 2024
Cardiology Department, Hohhot First Hospital, Hohhot, 010030, People's Republic of China.
Purpose: This study aimed to investigate the distribution patterns of PLA2G7 gene variants in Han Chinese patients with coronary heart disease (CHD), and their relationships with serum lipoprotein-associated phospholipase A2 (Lp-PLA2) levels and lipid profiles.
Methods: A total of 93 han Chinese CHD patients were recruited. Serum Lp-PLA2 levels were determined using enzyme-linked immunosorbent assay (ELISA), while comprehensive analysis of PLA2G7 gene polymorphisms was conducted through whole-exome sequencing.
Unveiling the Synergy of Serum Lipoprotein-Associated Phospholipase A2 and PLA2G7 Gene Polymorphism (rs1805017) as Key Determinants of Coronary Artery Disease Risk and Severity: Implications for Early Intervention.
Cureus
November 2024
Biochemistry, Nizam's Institute of Medical Sciences, Hyderabad, IND.
Background Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a key enzyme selectively expressed in unstable, rupture-prone atherosclerotic plaques. Previous research has established a strong link between the gene and the development of coronary artery disease (CAD). While traditional risk factors like cholesterol levels and blood pressure are valuable, there remains a need for more specific biomarkers to identify individuals at heightened risk of atherosclerosis before the onset of clinical symptoms.
View Article and Find Full Text PDFThe Role of Lp-PLA2 as a Mediator Between Serum Magnesium and Zinc Levels and Cardiovascular Risk in Patients With Metabolic Syndrome.
Cureus
October 2024
Physiology, All India Institute of Medical Sciences, Deoghar, IND.
Background: Metabolic syndrome (MetS) is a collection of conditions that includes abdominal obesity, low high-density lipoprotein (HDL) levels, high triglycerides, hypertension, and impaired glucose metabolism, all of which are risk factors for cardiovascular diseases. Of the biomarkers above, lipoprotein-associated phospholipase A2 (Lp-PLA2) has been highlighted as a critical link between inflammation and the pathogenesis of atherosclerosis, which strongly predicts cardiovascular events. Micronutrients like magnesium and zinc are essential in maintaining metabolic and cardiovascular health, but these micronutrient deficiencies occur frequently among individuals with MetS.
View Article and Find Full Text PDFLipoprotein-associated phospholipase A2 and its possible association with COPD development: a case-control study.
BMC Pulm Med
November 2024
Health Management Center, The First Affiliated Hospital (Southwest Hospital) of Army Medical University, No.30, Gaotanyan street, Shapingba District, Chongqing, 400038, China.
Background: The association of lipoprotein-associated phospholipase A2 (Lp-PLA2) with various cardiovascular events has been well-established. However, the exploration of its potential involvement in Chronic obstructive pulmonary disease (COPD) is currently limited. Therefore, our study aims to examine the relationship between Lp-PLA2 and pulmonary conditions, including emphysema, obstructive ventilatory dysfunction as well as small airway dysfunction, to provide further evidence of a possible association with COPD development.
View Article and Find Full Text PDFAssociation of plasma neurofilament light chain and Lipoprotein-related phospholipase A2 with motor subtypes of Parkinson's disease.
Neurosci Lett
November 2024
Department of Neurology, Tianjin Neurological Institute, Tianjin Medical University General Hospital, Tianjin, China. Electronic address:
Article Synopsis
- * Conversely, lipoprotein-related phospholipase A2 (Lp-PLA2) levels were lower in PD patients and showed potential for distinguishing between different motor subtypes of PD, particularly higher in tremor-dominant patients than those with postural instability and gait difficulty.
- * The study suggests that both NfL and Lp-PLA2 could serve as valuable biomarkers for diagnosing PD, warranting further research with larger patient groups to validate these findings.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!